Chinese deal activity in the US slumps to the lowest levels in 17 years. The figure contrasts with growing investments into mainland China.

Chinese deal activity in the US slumps to the lowest levels in 17 years. The figure contrasts with growing investments into mainland China.

Crystal Zhang FT Interview

Crystal Zhang, partner at ARC Group, was interviewed by Financial Times about the topic.

Read more here:

https://www.ft.com/content/42db9ff5-1589-416e-8337-601772af44c4

Continue reading

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

ARC Group Announces US$15 Million Investment Commitment in Cloudbreak Pharma Inc. (HKEX: 2592)

HONG KONG, 18 June 2026 — ARC Group today announced that it has committed to invest in Cloudbreak Pharma Inc. (HKEX: 2592), a clinical-stage ophthalmology biotechnology company with operations across the United States and China, following the signing of a share subscription agreement through its wholly owned subsidiary ARC Group International Limited. The transaction marks […]
Rising Together | ARC Dragon Boat Team Takes to the Water
Bio Green Med Solution, Inc. Announces Business Combination Agreement to Acquire Future NRG Sdn. Bhd.
Inside ARC Group | University of Nottingham Ningbo China

Please complete this form to download the case study

This field is for validation purposes and should be left unchanged.
*Required before submission